Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Summary

This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).

Timeline

Start

2013-04-24

Primary completion

2016-08-05

Completion

2016-08-05

Drugs

Indications